Creation: Biofilm Pharma prepares the next generation of AntiMicrobials

Since 2005, BioFilm Control is specialized in the detection of biofilms, cellular communities welcoming the development of antibiotic-resistant bacteria, responsible for infections which can be mortal. It is estimated that up to 10 million deaths will be caused by these infection in 2050.

While the first diagnostic test from Biofilm Control will be available on the market in 2018, the company has created in april 2017, BioFilm Pharma, specialized in the treatment of these biofilms.
BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment of “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for Health Care system in high-income countries (4 billions €).

BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy.
The company has already 5 compounds in its pipeline and is 3 years up to proof-of-concept in patients for potential blockbusters. It has already 2,4 M€ secured by a syndicate of historic investors or grants and it is looking for 20 M€ funds to engage CMC, preclinical and clinical studies.

BIOFILM PHARMA
Biopôle Clermont-Limagne
Thierry Bernardi
Phone: +33 (0) 473 333 980
Email : contact@biofilmphama.fr
Website: www.biofilmpharma.fr